Clinical Burden of Recurrent Disease in High-Risk Endometrial Cancer
The findings of this study suggest that DFS may be a useful surrogate for OS in high-risk endometrial cancer, though validation in trial-level meta-analyses is needed, and highlight the substantial burden associated with recurrent disease, as evidenced by the four-fold to eight-fold higher risk of mortality across comparative assessments of OS. Effective novel therapies are needed to reduce the considerable burden of disease recurrence in this population.
Authors
- Annalise Hilts
- Linda Duska
- Mu Cheng (ORCID: https://orcid.org/0000-0001-6831-0468)
- Yeran Li (ORCID: https://orcid.org/0000-0002-9777-7152)
- Yan Song (ORCID: https://orcid.org/0000-0002-7566-2813)
- Kalé Kponee-Shovein (ORCID: https://orcid.org/0000-0002-8008-4691)
- Vimalanand S. Prabhu (ORCID: https://orcid.org/0000-0003-1358-8846)
- Jasmine Lichfield
- Lei Chen (ORCID: https://orcid.org/0000-0002-0133-573X)
- Qi Hua
- Yezhou Sun
Institutions
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- MSD (UK) Limited (United Kingdom) (GB)
- University of Virginia (US)
- Analysis Group (United States) (US)
Publication Details
- Journal
- Oncology and Therapy
- Published
- 2025-07-12
- DOI
- https://doi.org/10.1007/s40487-025-00352-4
- Primary Topic
- Endometrial and Cervical Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- University of Southern California
- Centers for Disease Control and Prevention
- University of California, San Francisco
- National Cancer Institute